Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention

被引:15
|
作者
Youssef, Ali A.
Wu, Chiung-Jen
Hang, Chi-Ling
Cheng, Cheng-I
Yang, Cheng-Hsu
Chen, Chien-Jen
Chen, Yen-Hsun
Chai, Han-Tan
Chua, Sarah
Yeh, Kuo-Ho
Yip, Hon-Kan
机构
[1] Chang Gung Univ Coll Med, Dept Internal Med, Div Cardiol, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung 83301, Taiwan
[2] Suez Canal Univ Hosp, Dept Cardiol, Ismailia, Egypt
关键词
nitroprusside; no-reflow; PercuSurge device; slow-flow;
D O I
10.1253/circj.70.1538
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The present study tested the hypothesis that when administered in conjunction with a PercuSurge device for treatment of acute myocardial infarction (AMI), intracoronary (IC) administration of nitroprusside (NTP) is safe and superior to IC administration of NTP alone or nitroglycerin (NTG) for reversing slow-flow or no-reflow, both of which occur frequently during primary percutaneous coronary intervention (PCI). Methods and Results Sixty-two patients with ST-segment elevation AMI of < 12h duration undergoing primary PCI were enrolled. When the final Thrombolysis In Myocardial Infarction (TIMI) flow was normal (TIMI-3), NTG 200 mu g was administered first, followed by (5 min later) NTP 100,mu g via an intra-guiding catheter. When final TIMI flow was <= 2, NTG 200 mu g was given, followed by NTP 100 mu g via an export suction catheter advanced into the infract-related artery (IRA). Primary endpoint was epicardial blood flow (TIMI-flow), corrected TIMI frame counts, or microvascular circulation [myocardial blush (MB) grade]. Analytical results indicated that the final TIMI-3 flow was significantly higher in patients receiving NTP than in those receiving NTG therapy (100% vs 88.7%, p=0.023). As compared with NTG, NTP therapy significantly improved final MB grade (p < 0.0001) and corrected TIMI flame count time (p < 0.0001). Subgroup analysis demonstrated that final MB grade (p < 0.001) and corrected TIMI flame count time (p < 0.01) were significantly higher in patients (n=33) with than in patients (n=29) without the PercuSurge. No significant NTP related adverse events occurred, apart from insignificant transient hypotension. Conclusion IC administration of NTP is safe and superior to NTG for improving final epicardial blood flow and microvascular circulation in patients with AMI undergoing primary PCI. Combination therapy of PercuSurge device and NTP provided an additional benefit to NTP alone for improving microvascular circulation.
引用
收藏
页码:1538 / 1542
页数:5
相关论文
共 50 条
  • [1] Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction
    Wang, HJ
    Lo, PH
    Lin, JJ
    Lee, H
    Hung, JS
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 63 (02) : 171 - 176
  • [2] EFFECTS OF INTRACORONARY DILTIAZEM AND SODIUM NITROPRUSSIDE ON NO-REFLOW PHENOMENON AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Zhang-Qiang, C.
    Lang, H.
    Min, Y.
    Hong, W.
    Qiu-lin, Y.
    Lin-Feng, L.
    HEART, 2015, 101 : A40 - A40
  • [3] Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
    Zhao, Yu-Jun
    Fu, Xiang-Hua
    Ma, Xiao-Xiao
    Wang, Dong-Ying
    Dong, Qiu-Li
    Wang, Yan-Bo
    Li, Wei
    Xing, Kun
    Gu, Xin-Shun
    Jiang, Yun-Fa
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (02) : 479 - 484
  • [4] No-reflow phenomenon following percutaneous coronary intervention: An uncommon complication
    Safi, AM
    Kwan, TW
    ANGIOLOGY, 2000, 51 (03) : 247 - 252
  • [5] Predicting the no-reflow phenomenon following successful percutaneous coronary intervention
    Galiuto, L.
    Paraggio, L.
    Liuzzo, G.
    de Caterina, A. R.
    Crea, F.
    BIOMARKERS IN MEDICINE, 2010, 4 (03) : 403 - 420
  • [6] The Use of Intracoronary Sodium Nitroprusside to Treat No-Reflow after Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
    Tesic, Milorad B.
    Stankovic, Goran
    Vukcevic, Vladan
    Ostojic, Miodrag C.
    HERZ, 2010, 35 (02) : 114 - 118
  • [7] Intracoronary adenosine for the management of no-reflow phenomenon in the setting of primary percutaneous coronary angioplasty
    Deftereos, SG
    Lazaros, GA
    Rentoukas, EI
    Giannouleas, J
    Kouvousis, NM
    Foukarakis, MG
    Karvouni, E
    Zacharoulis, AA
    EUROPEAN HEART JOURNAL, 2000, 21 : 517 - 517
  • [8] Effect of Intracoronary Nitroprusside in Preventing No Reflow Phenomenon during Primary Percutaneous Coronary Intervention: A Meta-Analysis
    Zhao, Shijie
    Qi, Guoxian
    Tian, Wen
    Chen, Ling
    Sun, Yujiao
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2014, 27 (04) : 356 - 364
  • [9] Intracoronary nitroglycerin injection through a microcatheter for coronary no-reflow following percutaneous coronary intervention
    Park, Chang-Bum
    Cho, Jin-Man
    Kim, Dong-Hee
    Kim, Chong-Jin
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 214 : 401 - 403
  • [10] Role of Intracoronary Adrenaline in the Treatment of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention
    Simoni, Leonard
    Gjana, Armand
    Ziu, Kristi
    Dibra, Alban
    Goda, Artan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)